Strategies to control antipsychotic-induced weight gain

Psychoneuroendocrinology

Volumn 33, Issue 8, 2008, Pages 1171-

  Kapoor, Shailendra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMFEBUTAMONE; HISTAMINE H1 RECEPTOR; MELATONIN; MEMANTINE; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; TOPIRAMATE;

ANTIPSYCHOTIC INDUCED WEIGHT GAIN; BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG INDUCED DISEASE; HORMONE SUBSTITUTION; HUMAN; NOTE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; AWARENESS; BODY WEIGHT; BUPROPION; CLINICAL COMPETENCE; FRUCTOSE; HUMANS; HYPOGLYCEMIC AGENTS; MELATONIN; METFORMIN; OBESITY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 49049089129     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.04.008     Document Type: Note

References (6)

1. Gadde K.M., Zhang W., and Foust M.S. Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. J. Clin. Psychopharmacol. 26 (2006) 409-413
2. Han M., Deng C., Burne T.H., Newell K.A., and Huang X.F. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology (2008)
3. Khazaal Y., Fresard E., Rabia S., et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr. Res. 91 (2007) 169-177
4. Levy E., Agbokou C., Ferreri F., Chouinard G., and Margolese H.C. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J. Clin. Pharmacol. 14 (2007) e234-e239
5. Raskind M.A., Burke B.L., Crites N.J., Tapp A.M., and Rasmussen D.D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32 (2007) 284-288
6. Wu R.R., Zhao J.P., Jin H., et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299 (2008) 185-193